http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 30 Jul 2026 08:05:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Savara+wins+European+and+Australian+patents+for+Molbreevi+through+2041/26839309.html <p>Savara Inc. (Nasdaq: SVRA) announced that the European Patent Office has granted a patent covering the liquid formulation of Molbreevi, an investigational orally inhaled recombinant human GM-CSF being developed for autoimmune pulmonary alveolar proteinosis. European patent No. 4121000 provides protection through March 2041.</p><p>The Australian Patent Office separately granted patent No. 62/990,810 covering the same liquid formulation, also securing protection through March 2041.</p><p>In December 2025, Savara and PARI were granted a joint European patent covering the investigational drug-device combination of Molbreevi delivered via PARI's eFlow Nebulizer System, with protection extending through March 2043.</p><p>According to a statement from Savara's Chief Legal Officer http://www.streetinsider.com/Corporate+News/Savara+wins+European+and+Australian+patents+for+Molbreevi+through+2041/26839309.html Thu, 30 Jul 2026 08:05:22 -0400 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Press+Releases/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html <p class="bwalignc"> <i>-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54579559&amp;newsitemid=20260730546415&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=f67270d4ff3fc9507a7925afdc35506f" shape="rect"><b>Savara Inc.</b></a> (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has http://www.streetinsider.com/Business+Wire/Savara+Announces+European+and+Australian+Patent+Offices+Have+Granted+Patents+for+the+Liquid+Formulation+of+MOLBREEVI%2A%2C+Providing+Protection+in+Europe+and+Australia+Until+March+2041/26839305.html Thu, 30 Jul 2026 08:05:00 -0400 A.03718595 A.06822034 A.31066700 A.39807895 O.01272850 O.04906507 O.20026344 O.22422661 O.49194046 SVRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Savara+Inc++++++++++++++++For%3A+Jul+15++Filed+by%3A+Lutz+Robert+Matthew/26814499.html si-local-file:///var/storage/secattach/20260724/26814499.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Savara+Inc++++++++++++++++For%3A+Jul+15++Filed+by%3A+Lutz+Robert+Matthew/26814499.html Fri, 24 Jul 2026 18:25:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Savara+Inc++++++++++++++++For%3A+Jul+15++Filed+by%3A+Lutz+Robert+Matthew/26814499.html si-local-file:///var/storage/secattach/20260724/26814499.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Savara+Inc++++++++++++++++For%3A+Jul+15++Filed+by%3A+Lutz+Robert+Matthew/26814499.html Fri, 24 Jul 2026 18:25:00 -0400 O.01272850 SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA